Galderma en ImaBiotech smeden alliantie voor toegang tot Multimaging-diensten
LILLE, Frankrijk & SOPHIA ANTIPOLIS, Frankrijk–(BUSINESS WIRE)– Galderma, een toonaangevend farmaceutisch bedrijf in dermatologie, heeft gekozen voor Multimaging-diensten van ImaBiotech als ondersteuning van zijn medicijnontwikkeling.
Galderma koos voor Multimaging van ImaBiotech om de farmacokinetische, farmacologische, toxicologische fases en de formulering te combineren en te versnellen. Multimaging is een combinatie van weergavetechnieken (Quantitative MALDI, kleuring, immunokleuring) en gespecialiseerde software. Het platform heeft de capaciteit om op celniveau de verdeling van analytes kwantitatief te bestuderen. Het kan worden gebruikt bij medicijnonderzoek en -ontwikkeling en resulteert in een betere en snellere selectie van medicijnen voor de klinische fase.
Galderma and ImaBiotech Develop a Long-Term Alliance to Access Multimaging™ Services
LILLE, France & SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)– Galderma a leading pharmaceutical company in Dermatology has chosen ImaBiotech to support their drug development with innovative Multimaging™ services.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151109006135/en/
Galderma has chosen ImaBiotech’s Multimaging™ services to combine and accelerate its drug pharmacokinetic, pharmacology, toxicology and formulation phases. Multimaging™ is a combination of imaging techniques (Quantitative MALDI imaging, staining, immune-staining) associated with dedicated software. This platform has the capability to jointly study quantitatively the distribution of analytes at a cellular level. It can be used during drug discovery and development, resulting in a better and faster drug selection for clinical phase.
Galderma is interested in the capabilities of ImaBiotech’s MALDI imaging platform and would benefit from the Multimaging™ services to support their drug investigations. ImaBiotech will provide analysis of Galderma samples to investigate drug, metabolites and biomarker distribution quickly and efficiently.
Dr Laurent Hennequin, Director of Research and Dr Philippe Andres, Director of Global Evaluation, Galderma R&D “ We consider ImaBiotech as a key partner to help us to visualise our compounds in skin through imaging. Knowing the challenge which is the quantification and the localization of analytes, including biomarkers, in skin, we consider that ImaBiotech technologies can lead us quicker to better and safer products.”
Dr Jonathan Stauber, CEO of ImaBiotech adds ”We are more than proud to become a partner of Galderma, world-known as a major pharmaceutical company. This new partnership is a proof that our company and its Multimaging™ technology have become key players in the Molecular imaging field in less than a year.”
View source version on businesswire.com: http://www.businesswire.com/news/home/20151109006135/en/
Contacts
ImaBiotech
Jonathan Stauber, T: +33 (0) 320 164 091
PhD, ImaBiotech
Chief Executive Officer
E: contact@imabiotech.com
or
Ga lderma
Philippe Andres, T: +33 (0) 492 952 997
Galderma R&D
Director of Global Evaluation
E: philippe.andres@galderma.com
Check out our twitter: @NewsNovumpr